services-07 By Posted September 10, 2014 In services-072014-09-102014-09-10https://apyxmedical.com/wp-content/uploads/2018/12/apyx-logo-footer_orange-white_150w.pngApyx Medicalhttps://apyxmedical.com/wp-content/uploads/2018/12/apyx-logo-footer_orange-white_150w.png200px200px 0 Recent PostsAPYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKRENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTIONAPYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURINGAPYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023
